Wells Fargo has recently downgraded its investment rating for cell therapy company ARCELLX, INC. from "Overweight" to "Equal Weight".

However, the institution has simultaneously raised the target stock price from $100 to $115, demonstrating recognition of the company's long-term value. This rating adjustment reflects the analysts' balanced consideration between short-term risks and long-term potential. The upward revision of the target price may be based on ARCELLX's technological advancements in the CAR-T cell therapy field or positive signals from clinical trial data.